REGN shares have broken above the 200‑day moving average and are holding near the 50‑day EMA with rising volume, indicating a continued uptrend. Fundamentals are solid with Dupixent's EU CHMP approval expanding its pediatric market and boosting revenue outlook.

Investor sentiment remains highly positive as Dupixent's EU nod fuels optimism about growth and pipeline momentum. Market chatter and analyst upgrades reinforce a bullish bias.

While the expanded indication lowers execution risk, dependence on Dupixent revenue and potential competition remain long‑term concerns. Overall, pipeline diversification and strong cash generation support a bullish long‑term view.

Technical indicators show a bullish MACD crossover and RSI staying below overbought levels, while daily candles form higher highs and higher lows. Volume‑weighted average price (VWAP) remains under price, confirming upward pressure.